ADMA Biologics (ADMA) reported Q1 earnings late Wednesday of $0.11 per diluted share, up from $0.08 a year earlier.
Three analysts polled by FactSet expected $0.15.
Revenue in the three months ended March 31 rose to $114.8 million from $81.9 million a year earlier. Three analysts surveyed by FactSet expected $116.4 million.
The company raised 2025 revenue guidance to over $500 million from over $490 million and boosted the 2026 forecast to over $625 million from $605 million.
Three analysts expect $496.1 million this year and $629.7 million in 2026.
The board authorized a stock repurchase program of up to $500 million
The company's shares fell 4.7% in after-hours trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。